Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LRX712 in moderate knee osteoarthritis
NCT03355196Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing LRX712 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at Day 29. Started Nov 2017; status: completed.
02
Drugs
LRX712
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03355196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03355196.